regeneron_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): November 18, 2011 (November 18, 2011)

 
REGENERON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

 
New York       000-19034       13-3444607
(State or other jurisdiction of   (Commission File No.)   (IRS Employer Identification No.)
Incorporation)        
 

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
(Address of principal executive offices, including zip code)
 
(914) 347-7000
(Registrant's telephone number, including area code)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Item 8.01 Other Events.
 
     On November 18, 2011, Regeneron Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration approved EYLEA™ (aflibercept) Injection for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD).
 
     A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference into this Item.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
 
99.1       Press Release Announcing FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration, dated November 18, 2011.

 

SIGNATURES
 
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:  November 18, 2011 REGENERON PHARMACEUTICALS, INC.
     
     
  By:   /s/ Joseph J. LaRosa
    Name:Joseph J. LaRosa
    Title:Senior Vice President, General Counsel and Secretary
   

 

Exhibit Index
     
Number   Description
99.1       Press Release Announcing FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration, dated November 18, 2011.